ライフサイエンスコーパス: calcium channel blocker

1 orable outcomes when randomized to receive a calcium channel blocker.

2 The fourth compound, suloctidil, is a calcium channel blocker.

3 alcium channel blocker or ACE inhibitor plus calcium channel blocker.

4 ist, and 200 nM omega-agatoxin IVA, a P-type calcium channel blocker.

5 roup, but substituted a beta blocker for the calcium-channel blocker.

6 patients already receiving a beta blocker or calcium-channel blocker.

7 ted a mechanism of action similar to that of calcium channel blockers.

8 ular block, and those using beta-blockers or calcium channel blockers.

9 e intake of CsA, which might be abrogated by calcium channel blockers.

10 altered in the presence of L-, R- and T-type calcium channel blockers.

11 s and the inferiority of non-dihydropyridine calcium channel blockers.

12 ct would be stronger among persons not using calcium channel blockers.

13 phospholipid translocase and is inhibited by calcium channel blockers.

14 um by cobalt and was slowed by more specific calcium channel blockers.

15 rtate (NMDA) receptor antagonist MK 801, and calcium channel blockers.

16 utamate receptor antagonists, and sodium and calcium channel blockers.

17 alcium spikes, blocked by cadmium and L-type calcium channel blockers.

18 rdiovascular risks of magnesium sulphate and calcium channel blockers.

19 was activated by voltage and was blocked by calcium channel blockers.

20 ith sepsis were analyzed, 18.6% of whom used calcium channel blockers.

21 mpared with patients who have never received calcium channel blockers.

22 nt for differential likelihoods of receiving calcium channel blockers.

23 potent, selective, brain-penetrating T-type calcium channel blockers.

24 brain penetrant and selective triple T-type calcium channel blockers.

25 ent, selective, and brain-penetrating T-type calcium channel blockers.

26 ement for use of statins, beta-blockers, and calcium channel blockers.

27 d with a beta-blocker or non-dihydropyridine calcium channel blockers.

28 by SOC inhibitors, but not by voltage-gated calcium channel blockers.

29 received verapamil to evaluate the effect of calcium channel blockers.

30 ding concurrent use of CYP3A4 inhibitors and calcium-channel blockers.

31 ual variation in SBP was reduced the most by calcium-channel blockers (0.76, 0.67-0.85, p<0.0001).

32 CTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers, 3 of 3 RCTs (100%) of antiplat

33 (-5.76 mm Hg [95% CI -10.28 to -1.23]) or a calcium-channel blocker (-5.13 mm Hg, [-9.47 to -0.79])

34 ngiotensin-receptor blockers, beta-blockers, calcium channel blockers); (5) Most patients with hypert

35 The most commonly used medication class was calcium-channel blockers (55.2%, 55.0-55.4).

36 0.76; 95% confidence interval=0.74-0.78) and calcium channel blockers (adjusted hazard ratio=0.93; 95

37 Overdoses of calcium channel blocker agents result in hyperglycemia,

38 ergic blocker (beta-blocker) alone in 24%, a calcium channel blocker alone in 17%, digoxin alone in 1

39 A calcium channel blocker also mimicked NGF treatment.

40 Additionally, use of calcium channel blocker also shows a significant associa

41 Inhibition of Ca(2+) mobilization with calcium channel blockers also inhibits Ang-2 release.

42 re and after additional impairment (from the calcium channel blocker amlodipine).

43 s well as marked acute BP sensitivity to the calcium channel blocker amlodipine.

44 zyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (

45 or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedip

46 l 2.5-10 mg/d; n = 436) or a dihydropyridine calcium channel blocker, (amlodipine 5-10 mg/d; n = 217)

47 original trials used 3 different statins, a calcium-channel blocker, an angiotensin-converting enzym

48 For primary prevention, we used aspirin, a calcium-channel blocker, an angiotensin-converting-enzym

49 effects of incident diabetes associated with calcium channel blocker and angiotensin-converting enzym

50 Here we report that felodipine, an L-type calcium channel blocker and anti-hypertensive drug, indu

51 16%, a beta-blocker and digoxin in 14%, or a calcium channel blocker and digoxin in 14% of patients.

52 e depolarization was slightly inhibited by a calcium channel blocker and markedly inhibited by a Na(+

53 It was the first clinically used calcium channel blocker and remains in clinical use, alt

54 ented with a K(ATP) channel opener but not a calcium channel blocker and the other potentially arisin

55 The other 2 agents should include calcium channel blockers and angiotensin-converting enzy

56 f cases, VR-PAH has a pronounced response to calcium channel blockers and better survival than vasodi

57 ltures of human kidney epithelial cells with calcium channel blockers and by lowering extracellular c

58 Calcium channel blockers and calmodulin inhibitors added

59 Calcium channel blockers and calmodulin inhibitors incre

60 Calcium channel blockers and hydrochlorothiazide are imp

61 tients with DM were more commonly prescribed calcium channel blockers and long-acting nitrates at dis

62 e reveals inverse correlation between use of calcium channel blockers and lung cancer diagnosis.

63 Calcium channel blockers and renin-angiotensin system in

64 termine the association between prior use of calcium channel blockers and the outcome of patients adm

65 rug class use between cases and controls for calcium channel blockers and thiazides was noted.

66 For calcium channel blockers and thiazides, the matched odds

67 Diuretics are superior to calcium channel blockers and, at least in the short term

68 The opposite effects of calcium-channel blockers and beta blockers on variabilit

69 uretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin- ang

70 nsion, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alcohol, but not for diabe

71 ent for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics.

72 f defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere

73 sed by the antiseizure medication phenytoin, calcium channel blockers, and ciclosporin.

74 thmics), versus rate control (beta-blockers, calcium channel blockers, and digoxin) treatment strateg

75 olled in the groups receiving beta-blockers, calcium channel blockers, and digoxin, respectively.

76 blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metformin.

77 beta-Blockers, calcium channel blockers, and mineralocorticoid receptor

78 giotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calciu

79 Prostaglandin analogues, calcium channel blockers, and oral corticosteroids have

80 which is structurally related to therapeutic calcium channel blockers, and that a natural coding-regi

81 rate-control treatment with beta-blockers or calcium channel blockers, and the use of beta-blockers w

82 inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones have a

83 inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones justifi

84 ons were sensitive to membrane potential and calcium channel blockers, and were potentiated by niflum

85 Commonly used medications include calcium channel blockers, angiotensin receptor blockers

86 ated included beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers,

87 for AMI; whereas angiotensin-II-antagonists, calcium-channel blockers, angiotensin-converting-enzyme

88 (aOR 2.02, CI 1.03-3.96) and dihydropyridine calcium channel blockers (aOR 1.91, CI 1.03-3.55) were a

89 Calcium channel blockers are among the most commonly use

90 ce, the roles of gene therapy, hepcidin, and calcium channel blockers are being actively investigated

91 Conversely, the benefits of calcium channel blockers are increasingly recognized.

92 , either beta-blockers or nondihydropyridine calcium channel blockers are reasonable drugs in patient

93 Dihydropyridine calcium channel blockers are unlikely to have a clinical

94 High doses of calcium-channel blockers are indicated only in the minor

95 Calcium-channel blockers are metabolized by the cytochro

96 beta-Blockers and calcium-channel blockers are more effective than placebo

97 These findings support the use of calcium channel blockers as a strategy to minimize the n

98 he use of thiazide diuretics and long-acting calcium channel blockers as first-line therapy to treat

99 is assay, we identified fendiline, an L-type calcium channel blocker, as a specific inhibitor of K-Ra

100 this study further support an association of calcium channel blockers, as well as thiazides, with CEE

101 use, although it has been eclipsed by other calcium channel blockers because of its short half-life

102 ication (beta = 0.75; P = .04), specifically calcium channel blockers (beta = -1.02; P < .001), was s

103 Polytherapy with a calcium channel blocker, beta-blocker, or angiotensin-co

104 compared with pharmacy records for statins, calcium channel blockers, beta-blockers, and bisphosphon

105 Suppression of VA may be achieved using calcium-channel blockers, beta-adrenergic blockers, and

106 The effects of nitrates, calcium-channel blockers, beta-blockers, and statins on

107 edium contains nitrendipine, a voltage-gated calcium channel blocker, but fails to occur when applica

108 uld be terminated by nitrendipine, an l-type calcium channel blocker, but not by the Na channel block

109 ivated cation channels but was halved by the calcium channel blocker cadmium and abolished by tetrodo

110 The voltage-gated calcium channel blocker cadmium chloride did not alter t

111 neurons was not altered by the voltage-gated calcium channel blocker cadmium chloride that blocks bot

112 gic mEPSC was unaltered by the voltage-gated calcium channel blocker cadmium, and was abolished by th

113 Oscillations were unaffected by the calcium channel blockers cadmium and nickel and by block

114 Experimental studies suggest that calcium channel blockers can improve sepsis outcome.

115 Calcium channel blockers (CCB) are widely prescribed ant

116 Calcium channel blockers (CCB) improve TB treatment outc

117 gen tension, inhaled nitric oxide (iNO), and calcium channel blockers (CCB) in 10 patients with BPD w

118 ionally, intake of oral hypoglycemic agents, calcium channel blockers (CCB), insulin, and diuretics w

119 ptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity.

120 dult patients with favorable prognosis using calcium-channel blocker (CCB) therapy.

121 ), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%),

122 crolimus while controlling for the effect of calcium channel blockers (CCBs) and supragingival plaque

123 Calcium channel blockers (CCBs) are an important class o

124 Calcium channel blockers (CCBs) are prescribed to patien

125 cancer risk associated with long-term use of calcium channel blockers (CCBs) or angiotensin-convertin

126 The potential of calcium channel blockers (CCBs) to induce gingival enlar

127 erting enzyme inhibitors, beta-blockers, and calcium channel blockers (CCBs) were identified.

128 Little is known about associations of calcium channel blockers (CCBs) with outcomes in patient

129 iotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), alpha-blockers, and ang

130 450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs).

131 ing-enzyme inhibitors [ACEi], beta blockers, calcium-channel blockers [CCBs], or diuretics) with foll

132 ccepted mechanism of action of nifedipine, a calcium-channel blocker clinically used in patients with

133 Among older adults taking a calcium-channel blocker, concurrent use of clarithromyci

134 Moreover, embryos grown in calcium channel blocker-containing medium had hearts tha

135 Fatty acid loading or calcium channel blockers could decrease myocardial (18)F

136 nd burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat

137 control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Pa

138 or stroke, diuretics plus ACE inhibitors or calcium channel blockers did not differ from diuretics p

139 Other classes of L-type calcium channel blockers did not mislocalize K-Ras, sugg

140 CE inhibitors, non-ophthalmic beta blockers, calcium channel blockers, diuretics, and angiotensin rec

141 tor blockers, alpha-blockers, beta-blockers, calcium channel blockers, diuretics, nitrates, statins,

142 s to account for the use of beta-blockers or calcium channel blockers during follow-up did not alter

143 Ethosuximide, a T-type calcium channel blocker, eliminated busting in lesioned

144 treatments (eg, nitrates, beta blockers, and calcium-channel blockers), emerging anti-angina treatmen

145 Most calcium channel blockers exhibit state-dependence (i.e.,

146 Autoantibodies, vascular features, use of calcium channel blockers, extent of pulmonary function,

147 (ATP) channel opener pinacidil (n=6) and the calcium channel blocker flunarizine (n=6).

148 X-sensitive sodium currents and a mixture of calcium channel blockers for calcium currents) and ionic

149 Nevertheless, the utility of calcium channel blockers for heart disease is limited be

150 the gabapentinoids for neuropathic pain and calcium channel blockers for otherwise intractable pain

151 coding insect specific sodium, potassium and calcium channel blockers for their ability to improve th

152 Women treated with a diuretic plus a calcium channel blocker had an 85% greater risk of CVD d

153 Voltage-dependent calcium channel blockers had little effect on the initia

154 Nimodipine, an L-type calcium channel blocker has been shown to reduce iron-in

155 Use of calcium channel blockers has been found to improve sepsi

156 We have shown previously that prenylamine, a calcium channel blocker, has potent local anesthetic act

157 As calcium channel blockers have been safely used in clinic

158 ntal studies, and in a few clinical studies, calcium channel blockers have been shown to ameliorate s

159 Oxygen radical scavengers and calcium channel blockers have been shown to enhance func

160 .33; 95% confidence interval, 1.13 to 1.57), calcium channel blockers (HR, 1.57; 95% confidence inter

161 ontrolling anginal symptoms (Dihydropyridine calcium channel blockers if already on a beta-blocking a

162 y on a beta-blocking agent and rate-limiting calcium channel blockers if beta blockers are contraindi

163 ective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline.

164 ngiotensin-converting enzyme inhibitors, and calcium channel blockers in the treatment groups was sim

165 rvational data to suggest a central role for calcium channel blockers in the treatment of microvascul

166 tory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure

167 um channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid ind

168 ished by omitting Na+ or by applying peptide calcium channel blockers, indicating that nAChRs trigger

169 econtamination following a potentially toxic calcium channel blocker ingestion (1D); 2) as first-line

170 We were surprised to discover that calcium channel blockers inhibited TXNIP expression in I

171 re, pretreatment of cells with nifedipine, a calcium channel blocker, inhibited vanadium-induced NFAT

172 hod for developing novel genetically encoded calcium channel blockers inspired by Rem, a small G-prot

173 correlate directly with the severity of the calcium channel blocker intoxication.

174 This study determines whether the use of calcium channel blockers is associated with a decreased

175 The fungal calcium channel blocker KP4 inhibited the [Ca(2+)](c) re

176 leakage were inhibited in RPS2 plants by the calcium channel blocker LaCl(3), highly correlating thes

177 of extracellular calcium or addition of the calcium channel blocker lanthanum (0.5 mM) inhibited the

178 otensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective sero

179 resent studies we have reported that a novel calcium channel blocker, LY393615, with good bioavailabi

180 The long-term use of calcium channel blockers may be protective, but newer ag

181 Moreover, antiepileptics and calcium channel blockers may provide repurposing opportu

182 Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced

183 ng from both a KATP channel activation and a calcium channel blocker mechanism.

184 Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50% of patients).

185 Nifedipine, a calcium channel blocker, most robustly ameliorated the m

186 with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1).

187 nsin-converting enzyme inhibitors (n = 437), calcium-channel blockers (n = 223), diuretics (n = 226),

188 reduced by 5-HT, and fully abolished by the calcium channel blocker nickel.

189 ent of ureteral relaxation, we show that the calcium channel blocker nifedipine and the Rho-kinase in

190 Although the L-type voltage-gated calcium channel blocker nifedipine did not suppress calc

191 ed calcium entry blocked DIR, but the L-type calcium channel blocker nifedipine did not.

192 nnel agonist Bay K 8644 and inhibited by the calcium channel blocker nifedipine in a dose-dependent m

193 ATP)) channel opener diazoxide or the l-type calcium channel blocker nifedipine mimicked the effect o

194 The calcium channel blocker nifedipine reduced, and the sarc

195 primary target is another channel, e.g. the calcium channel blocker nifedipine, the sodium channel b

196 First, we observed that the L-type calcium channel blockers nifedipine and verapamil effect

197 ium release, and the presence of impermeable calcium channel blockers nifedipine, SKF96365, or LaCl3,

198 compare the effectiveness and safety of the calcium-channel blocker nifedipine and the oxytocin inhi

199 Oxidation of the calcium-channel blocker nifedipine is measured using UV-

200 ceptor blockers (phentolamine, labetalol), a calcium channel blocker (nifedipine), and splanchnic vas

201 The L-type calcium channel blocker, nifedipine, significantly atten

202 This effect was mimicked by the calcium channel blocker, nifedipine.

203 ory reactivation by the L-type voltage-gated calcium channel blocker nimodipine interferes with the a

204 The L-type calcium channel blockers nimodipine and nifedipine aboli

205 +) but not by Mg(2+) or the classical l-type calcium channel blocker, nitrendipine.

206 uced in patients receiving CsA paralleled by calcium channel blockers nor significantly reduced in pa

207 ination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectiv

208 s study was undertaken to investigate L-type calcium channel blockers of the dihydropyridine class fo

209 oprotective role for centrally acting L-type calcium channel blockers of the dihydropyridine class in

210 Calcium channel blockers of the phenylalkylamine family

211 el of alanine mutants of the insect-specific calcium channel blocker omega-atracotoxin-Hv1a.

212 ed by targeted delivery of the voltage-gated calcium channel blocker omega-conotoxin GVIA.

213 ot suppress calcium oscillations, the N-type calcium channel blocker omega-conotoxin inhibited this s

214 The effects of enzyme inhibitors and calcium channel blockers on the actions of the NO donor

215 ts should continue to take beta-blockers and calcium channel blockers on the day of surgery.

216 ffect of nilvadipine, a dihydropyridine-type calcium channel blocker, on Abeta induced vasoconstricti

217 plus either ACE inhibitor, beta-blocker, or calcium channel blocker or ACE inhibitor plus calcium ch

218 population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is rec

219 oices should be a long-acting diuretic and a calcium-channel blocker or a beta-blocker, respectively.

220 Patients given calcium-channel blockers or alpha blockers had a 65% (ab

221 All randomised controlled trials in which calcium-channel blockers or alpha blockers were used to

222 se all randomised controlled trials in which calcium-channel blockers or alpha blockers were used to

223 ]; P = .002), and the use of dihydropyridine calcium channel blockers (OR, 9.24 [95% CI, 1.35-63.23];

224 therapy with an ACE inhibitor, beta-blocker, calcium channel blocker, or diuretic, and 4493 (23%) wer

225 yme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in th

226 e inhibitors, angiotensin-receptor blockers, calcium channel blockers, or beta blockers) was signific

227 m as it did not replicate for beta-blockers, calcium channel blockers, or diuretics.

228 No adequate trials of dexamethasone, calcium channel blockers, or magnesium sulphate have yet

229 ngiotensin-receptor blockers, beta blockers, calcium-channel blockers, or direct renin inhibitors (pr

230 ngiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics and the

231 ngiotensin receptor blockers, beta blockers, calcium channel blockers, other BP medications, aspirin,

232 eding index (P=0.001) and concomitant use of calcium channel blockers (P=0.029); in CsA and Tcr group

233 le sex, diabetes status, insulin use, use of calcium channel blocker, panendoscopic examination, hype

234 no history of CVD, a 2-drug-class regimen of calcium channel blockers plus diuretics was associated w

235 rovide a management approach for adults with calcium channel blocker poisoning.

236 In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before ind

237 Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more

238 gents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the pre

239 ial treatment of systemic corticosteroid and calcium channel blocker, remarkable improvement was noti

240 Replacement of calcium channel blockers resulted in the largest potenti

241 lcium influx was blocked by the nonselective calcium channel blockers ruthenium red, 1-(beta-[3-(4-me

242 statins, histamine H2-receptor blockers, or calcium-channel blockers seems to prevent Alzheimer's di

243 diabetic mice with cilnidipine, an N-/L-type calcium channel blocker, showed a reduction in albuminur

244 ore severe digital tip ulcers, but they used calcium channel blockers significantly less frequently (

245 ith cyclosporin A and concomitantly taking a calcium channel blocker since transplant were entered in

246 Treatment with the calcium channel blocker SK&F 96365 inhibited translocati

247 ibited by the calcium chelator BAPTA-AM, the calcium channel blocker SK&F 96365, and calpeptin, an in

248 x was also inhibited by omega-agatoxin-TK, a calcium channel blocker specific for Ca(v)2.1 channels.

249 First-generation calcium channel blockers such as verapamil are a widely

250 On subgroup analysis, calcium channel blockers tend to be more beneficial to p

251 veal a universal method for developing novel calcium channel blockers that may be extended to develop

252 gene transfer of Gem functions as a genetic calcium channel blocker, the local application of which

253 In this national cohort study, preadmission calcium channel blocker therapy before sepsis developmen

254 Patients who responded to calcium channel blocker therapy had metabolic profiles s

255 patients showing long-term improvement with calcium channel-blocker therapy.

256 phenylalkylamine (PAA), and it was the first calcium channel blocker to be used clinically.

257 of hearts with diltiazem, a specific L-type calcium channel blocker, to eliminate the involvement of

258 commendations for the stepwise management of calcium channel blocker toxicity.

259 ients with sepsis, of which, 19,742 received calcium channel blocker treatments prior to the admissio

260 The association between calcium channel blocker use and sepsis outcome was deter

261 test the association between dihydropyridine calcium channel blocker use and the time to important mi

262 Prior calcium channel blocker use is associated with reduced m

263 Concurrent calcium channel blocker use minimizes or negates the inv

264 Prior calcium channel blocker use was not associated with chan

265 found no evidence of effect modification by calcium channel blocker use, possibly because of modest

266 ations and to examine effect modification by calcium channel blocker use, using linear regression and

267 t smoking, prior cardiovascular disease, and calcium channel blocker use.

268 ministration of artemether and nimodipine, a calcium channel blocker used to treat postsubarachnoid h

269 nsidering large baseline differences between calcium channel blocker users and nonusers, a propensity

270 hrombin levels, which were less decreased in calcium channel blocker users.

271 ensity-matched cohort (20.2% vs 32.9% in non-calcium channel blockers users; p = 0.009) and in multiv

272 In sharp contrast, the L-type calcium channel blocker verapamil markedly decreased S1P

273 ivo, we administered the clinically approved calcium channel blocker verapamil to obese mice.

274 sed in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER)

275 Calcium channel blockers (verapamil, lanthanum) can also

276 erindividual variation in SBP was reduced by calcium-channel blockers (VR 0.81, 95% CI 0.76-0.86, p<0

277 Monotherapy with calcium channel blockers vs diuretics was associated wit

278 ratios for diabetes, insulin use and use of calcium channel blocker was 1.133 (1.074, 1.195), 1.414

279 Use of calcium channel blocker was associated with a reduced 30

280 concomitantly treated with cyclosporin and a calcium channel blocker was associated with functional p

281 Prior use of calcium channel blockers was associated with improved 30

282 onferroni correction was applied, the use of calcium channel blockers was most strongly associated wi

283 ribing clarithromycin vs azithromycin with a calcium-channel blocker was associated with a higher ris

284 Instead of its known function as an L-type calcium channel blocker, we found that amlodipine is abl

285 iew to creating a focally applicable genetic calcium channel blocker, we overexpressed the ras-relate

286 -reported use of statins, beta-blockers, and calcium channel blockers were all 95% or greater.

287 In addition, the effects of potassium and calcium channel blockers were also tested for comparison

288 Statins, beta-blockers, and calcium channel blockers were each reported by over 15%

289 For the prevention of heart failure, calcium channel blockers were inferior and diuretics wer

290 The non-dihydropyridine calcium channel blockers were significantly inferior to

291 Calcium channel blockers were superior to other drugs fo

292 Nitroglycerin as needed and a beta- or calcium-channel blocker were allowed.

293 t failure is increased in patients receiving calcium channel blockers when compared with those receiv

294 onotoxin CVIE, a potent and selective Cav2.2 calcium channel blocker with proposed antinociceptive ac

295 orming alpha1-subunits can be converted into calcium channel blockers with tunable selectivity, kinet

296 Nimodipine is a calcium-channel blocker with specific cerebral vasodilat

297 alpha blockers was 1.54 (1.29-1.85) and for calcium-channel blockers with steroids was 1.90 (1.51-2.

298 rst drug (with or without digoxin), 54% with calcium channel blockers (with or without digoxin), and

299 enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reduc

300 holesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.